Abstract Introduction Recurrence after curative-intent therapy remains a major challenge in colorectal cancer (CRC) and a leading cause of cancer-related death. Novel biomarkers are needed to enable detection of molecular residual disease (MRD) and support individualized treatment decisions. Circulating tumour DNA (ctDNA) has shown potential as a promising biomarker for MRD detection and recurrence risk stratification. Methods In this prospective multicentre study, patients with stage I–III CRC undergoing curative-intent treatment, were enrolled across 7 Swedish centres between 2020 and 2024. Surveillance included CT and CEA at 1 and 3 years. ctDNA was analysed using a tumour-informed, structural variant–based assay. Plasma samples were obtained preoperatively and postoperatively at 4–6 weeks, 3 and 6 months, 1 and 2 years. The primary endpoint was the association between ctDNA and recurrence-free interval (RFI). Results In total, 398 patients (239 colon, 159 rectal cancer) with a median age of 69 years (29–83) were included. Postoperative ctDNA positivity at any time was strongly associated with recurrence (HR 33.97; 95% c.i. 16.98–67.97), including both colon (HR 32.33; 95% c.i. 12.81–81.62) and rectal cancer (HR 104.46; 95% c.i. 22.66–481.54). Three-year RFI after definitive treatment was 21% (95% c.i. 10–46%) for ctDNA-positive patients compared with 91% (95% c.i. 86–96%) for ctDNA-negative patients. Among patients with positive ctDNA at 4–6 weeks, omission of ACT was associated with worse outcomes (2-year RFI 42 versus 61%). Discussion This nationwide study confirms the prognostic significance of ctDNA in colon cancer and adds new evidence supporting its clinical relevance in rectal cancer, highlighting its potential for personalized treatment decisions.